Skip to content

Curcumin in Kidney Transplant Recipients

A Pilot 12 Month, Randomized, Controlled Trial of Curcumin in Kidney Transplant Recipients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03935958
Enrollment
14
Registered
2019-05-02
Start date
2019-11-01
Completion date
2027-05-31
Last updated
2026-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorder Related to Renal Transplantation

Keywords

kidney transplantation, inflammation, vascular dysfunction, cognitive impairment, oxidative stress, graft function

Brief summary

The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.

Detailed description

Kidney transplant recipients are at increased risk of death from cardiovascular disease (CVD). Inflammation, oxidative stress and vascular dysfunction (impaired endothelial function and increased large elastic artery stiffness), are highly prevalent in kidney transplant recipients and contribute to the high incidence of CVD in this patient population. The most common cause of kidney transplant failure is interstitial fibrosis and tubular atrophy (IFTA). The incidence of IFTA is as high as 50% of kidney transplants at 1 year after transplantation. The pathophysiology of IFTA is not well understood. Possible mechanisms include chronic rejection or injury, inflammation, and drug toxicity. Kidney transplant recipients suffer from high rates of cognitive decline for which the investigators lack effective therapies. Thus, therapeutic interventions targeting inflammation, oxidative stress, vascular dysfunction, and cognitive impairment are a priority. Curcumin may have positive effects in terms of cardiovascular and nephroprotection because of its antibacterial, antiviral, anti-inflammatory and anti-oxidative effects. The aim of this study is to elucidate the role of curcumin as a nutritional strategy to reduce cardiovascular risk factors as well as inflammation and oxidative stress in kidney transplant recipients. The study aims to examine if curcumin will improve endothelial function by reducing markers of inflammation and oxidative stress. In addition, the study will evaluate the potential benefit of curcumin on cognitive function in kidney transplant recipients. Curcumin is a natural polyphenol with anti-inflammatory and antioxidant characteristics. Preliminary data indicate that curcumin administration improves endothelial dysfunction by reducing oxidative stress and inflammation and may improve cognitive function. The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients. Objectives: 1. Evaluate the effects of curcumin on kidney transplant graft function 2. Evaluate the effects of curcumin supplementation on cognitive function. 3. Evaluate the effects of curcumin on diabetes and cardiovascular outcomes 4. Evaluate the effects of curcumin on systemic and endothelial cell markers of inflammation and oxidative stress. Methods: Patients will be randomized 1:1 to receive either curcumin or placebo starting at the time of transplant or up to 2 weeks prior to transplant. Patients will be followed per standard of care for kidney transplant recipients. Additional blood (30mL) and urine samples will be drawn prior to transplant and at 3, 6 and 12 months post-transplant to be used for future analysis. There will be a total of 4 visits for this study. Additionally, two questionnaires will be distributed at each visit.

Interventions

DIETARY_SUPPLEMENTCurcumin

Patients will receive curcumin 2000 mg a day, for 12 months

OTHERPlacebo

Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER
Verdure Sciences
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

participants will not know if they are receiving curcumin or placebo

Intervention model description

20 participants in supplement (receiving curcumin) group 20 participants in control (receiving placebo) group randomization 1:1

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. The subject is a recipient of a living donor or deceased donor kidney only transplant 2. The subject is \> 18 years of age

Exclusion criteria

1. The subject has had a multi-organ transplant 2. Subjects that were taking curcumin pre-transplant

Design outcomes

Primary

MeasureTime frameDescription
Graft Outcomes12 monthsChange in GFR at 3, 6 and 12 months
Cognitive function & Pain12 monthsChange in Neuro-QOL Item Bank v2.0 at 0, 3, 6, and 12 months
Inflammation and oxidative stress12 monthsMarkers of inflammation and oxidative stress at 0,3,6, \& 12 months

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPierpaolo Di Cocco, MD, PhD

University of Illinois at Chicago

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 10, 2026